Theratechnologies Inc TH.TO is expected to show a fall in quarterly revenue when it reports results on July 9 for the period ending May 31 2025
The Montreal Quebec-based company is expected to report a 20.3% decrease in revenue to $17.548 million from $22.02 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Theratechnologies Inc is for a loss of 1 cent per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Theratechnologies Inc is $3.80, about 15.8% above its last closing price of $3.20
This summary was machine generated July 4 at 12:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)